Beruflich Dokumente
Kultur Dokumente
Investor Presentation
February 22, 2017
Safe Harbor
Forward-Looking Statements
This presentation includes statements that may be forward-looking statements. The words believe, expect, anticipate,
project, forecast and similar expressions, among others, generally identify forward-looking statements. Forward-looking
statements used in this press release include those with respect to revenue growth and path to profitability, market
opportunity and growth, timeline for Nellix PMA and other regulatory approvals, and revenue guidance for 2017. Endologix
cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited
to, competition from other products, changes to laws and regulations applicable to our industry, progress of our ongoing
clinical trials, clinical trial results, decisions and the timing of decisions of regulatory authorities regarding our products and
potential future products, delays in process enhancements and new product launches, market acceptance of our products,
and risks relating to foreign currency fluctuations. Additional information about the factors that may affect Endologixs
operations and results is set forth in Endologixs annual and periodic reports filed with the Securities and Exchange
Commission (the SEC). Endologix undertakes no obligation to release publicly any revisions to forward-looking statements
as a result of subsequent events or developments, except as required by law.
In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and currently
not approved in any market
2
Revolutionizing Aortic Care for Life
5
TREAT MORE PATIENTS
MORE EFFECTIVELY
Standard Anatomy
CAUTION Endologix products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding
product availability. Prior to use, refer to the Instructions for Use for complete and specific indications, contraindications, all warnings and precautions. Rx only.
Nellix 2-Year Clinical Results EVAS Global Registry
Freedom from
Freedom from
Aneurysm-Related
Persistent Endoleaks
Mortality
98% 97%
37 %
complex Secondary Freedom from
Interventions for Cardiovascular
Type II Endoleaks Mortality
0% 99%
These data continue to support positive outcomes in a real world patient population that
had no screening or anatomical restrictions at enrollment, and constitute the broadest
range of aortic anatomies for any prospective endovascular AAA study.
2017 2018
Q1 Q2 Q3 Q4 Q1 Q2
FDA Review
*Estimated milestones and approval based upon Gen1 device and current timelines and assumptions
In the U.S., Nellix is limited to investigational use only. 9
Ovation Clinical Results - LIFE Registry
Fast Track EVAR with Ovation is the safest, least invasive path to
faster discharge, fewer readmissions and lower hospital costs
30-day results Ovation LIFE EVAR Traditional EVAR
MAE 0.5% 3-4%
1
Not device/procedure related
ICU 0 1.4 2
days
1.6% 8%
3,4
30-day Readmission
1. 30d MAE rates for commercially available EVAR devices per US FDA SSED reports and post market global registries. Data on file. 2. Premier EVAR. 3. Chen SL et al. Perioperative Risk Factors for Readmission
10
Following EVAR. Presented at SCVS, 2016. 4. Gupta PK, et al. Unplanned readmissions after vascular surgery. J Vasc Surg 2014;59:473-82.
Ovation Alto and Nellix ChEVAS Expand Treatment to Complex AAA Patients
*Based on anticipated FDA Labeled Indications. Derived from M2S Database of 43,000 AAA CT Scans. Represents estimated treatment applicability with Ovation and Nellix. In the
U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and currently not approved in any market. 11
Patient Applicability and Market Opportunity
Total ELGX
TRADITIONAL 40% 55% 69% 80% 80%
TOTAL
ELGX
*Based on existing and estimated FDA Labeled Indications. Derived from M2S Database of 43,000 AAA CT Scans, other sources and company estimates. Represents treatment applicability based upon
company estimates, anticipated labeling and currently available information. In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and not
currently approved in any market. 12
Broadest Patient Applicability
77%
19% ChEVAS & Alto
Endologix
Cook Gore Medtronic
*Based on existing and estimated FDA Labeled Indications. Derived from M2S Database of 43,000 AAA CT Scans, other sources and company estimates. Represents treatment
applicability with AFX, Ovation and Nellix 3.5/Gen2, based upon company estimates, anticipated labeling and currently available information. In the U.S. Nellix is limited to
investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and not currently approved in any market. 13
New Product Pipeline*
Arg/ US
AP US Japan China
Brazil Gen2
EU LA AP US
Arg/
AP LA Japan
Brazil
EU AP US LA Japan
AP LA
Asia US EU Latin
Pacific America
ELEVATE IDE
EVAS
Nellix 2-Year Results NextGen
LUCY
LEOPARD
ELEVATE2 Thoracic
ChEVAS IDE
Sales Force Training Complete
*Based on current anticipated regulatory timelines and approvals. In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices
and currently not approved in any market 15
2017 Sales Guidance
$152M - $159M
1% - 5% FY 2017 Revenue
~$41M $193-200M
(2)%
KEY ASSUMPTIONS
1H sales disruption due to
previous AFX CE and
manufacturing issues
Sequential quarterly sales
growth expected as AFX
issues resolve, Ovation
growth in U.S. and Launch of
Alto in Europe
16
Summary